Quantcast

Data show clinical benefit from mitral valve clip device

WASHINGTON, DC — SEPTEMBER 21, 2010 — A percutaneous mitral valve clip designed to stop mitral valve regurgitation demonstrated clinical benefit as measured by the degree of mitral regurgitation, according to a study presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. Mitral valve regurgitation is one of the most common forms of heart disease.

The study was led by James Hermiller, MD, Director of Cardiovascular Intervention at the St. Vincent Heart Center of Indiana (Indianapolis, IN.)

“Significant measures of clinical benefit are observed one year following successful therapy,” said Dr. Hermiller.

The study, EVEREST II, is a prospective, multi-center, randomized controlled trial designed to compare the safety and effectiveness of the MitraClip System with mitral valve surgery in the treatment of mitral regurgitation (MR). Measures of 12-month clinical benefit, defined as improvements in left ventricular (LV) function and symptomatic improvement, were evaluated for the Device Group and Control Group, and have been previously reported. However, observed clinical benefit by 12 month MR grade has not been reported.

Significant improvement in LV function, NYHA Functional Class, and Quality of Life scores was observed for all device patients with ongoing success (MR≤2+ at 12 months). Patients with MR reduced to 1+, 1+ to 2+, or 2+ at 12 months demonstrated marked clinical benefit, with significant improvements noted from baseline to 12 months.

A detailed analysis of these data will be presented during The ‘Best of the Best’ TCT 2010 Abstracts Session at 3:16 PM on Friday, September 24 in the Main Arena at the Washington Convention Center.

About CRF and TCT

The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from over 90 countries around the world to present and discuss the latest developments in the field.

For more information, visit www.crf.org.




The material in this press release comes from the originating research organization. Content may be edited for style and length. Want more? Sign up for our daily email.

2 thoughts on “Data show clinical benefit from mitral valve clip device”

  1. It was something of great pleasure coming across your site the other day. I came up here now hoping to come across something new. I was not dissatisfied. Your well thought out ideas upon new approaches on this area were helpful and a great help to me and my spouse. Thank you for leaving out time to write out these things plus for sharing your opinions.

    mitral valve surgery

  2. I appreciate your post and will subscribe to your rss feed so I can read anytime. Wonderful information Ours is an educational site about heart valve,for more information about Mitral valve prolapse (MVP), mitral valve prolapse symptoms,mitral valve prolapse treatment, mitral valve prolapse syndrome, symptoms of mitral valve prolapse, mitral valve prolapse surgery Please visit themitralvalve.org

Comments are closed.